Novel Triazolopyrimidine‐Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases

Citations Over TimeTop 12% of 2015 papers

Abstract

The cannabinoid receptor 2 (CB2) system is described to modulate various pathological conditions, including inflammation and fibrosis. A series of new heterocyclic small-molecule CB2 receptor agonists were identified from a high-throughput screen. Lead optimization gave access to novel, highly potent, and selective (over CB1) triazolopyrimidine derivatives. A preliminary structure-activity relationship was established, and physicochemical properties in this compound class were significantly improved toward better solubility, lipophilicity, and microsomal stability. An optimized triazolopyrimidine derivative, (3S)-1-[5-tert-butyl-3-[(1-cyclopropyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol (39), was tested in a kidney ischemia-reperfusion model, in which it showed efficacy at a dose of 10 mg kg(-1) (p.o.). A significant depletion of the three measured kidney markers indicated a protective role of CB2 receptor activation toward inflammatory kidney damage. Compound 39 was also protective in a model of renal fibrosis. Oral treatment with 39 at 3 mg kg(-1) per day significantly decreased the amount of fibrosis by ∼ 40% which was induced by unilateral ureter obstruction.

Related Papers

• → Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor(2000)541 cited
• → Targeting cannabinoid agonists for inflammatory and neuropathic pain(2007)101 cited
• → Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors(2004)99 cited
• → Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists(2008)88 cited
• → Identification and biochemical analyses of selective CB2 agonists(2019)10 cited